Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sjögren’s syndrome

References

• Nocturne G, Cornec D, Seror R, et al. Use of biologics in Sjögren’s syndrome. Rheum Dis Clin North Am. 2016;42:407–417.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Moutsopoulos HM. Sjögren’s syndrome. Annu Rev Pathol Mech Dis. 2014;9:273–285.
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Lewis M, Pitzalis C. Ectopic lymphoid neogenesis in rheumatic autoimmune diseases. Nat Rev Rheumatol. 2017;13:141–154.
   PubMed Web of Science ®Google Scholar
• Barone F, Bombardieri M, Manzo A, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren’s syndrome. Arthritis Rheum. 2005;52:1773–1784.
   PubMed Web of Science ®Google Scholar
• Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren’s syndrome. Ann Rheum Dis. 2011;70:1363–1368.
   PubMed Web of Science ®Google Scholar
• Risselada AP, Kruize AA, Goldschmeding R, et al. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren’s syndrome. Ann Rheum Dis. 2014;73:1537–1540.
   PubMed Web of Science ®Google Scholar
• Risselada AP, de Hair M, Kruize AA, et al. Lymphocytic focus score as a prognostic tool. Ann Rheum Dis. 2015;74:e31.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. Pnas. 2006;103:2770–2775.
   PubMed Web of Science ®Google Scholar
• Båve U, Nordmark G, Lövgren T, et al. Activation of the type I interferon system in primary Sjögren’s syndrome: A possible etiopathogenic mechanism. Arthritis Rheum. 2005;52:1185–1195.
   PubMed Web of Science ®Google Scholar
• Hjelmervik TOR, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren’s syndrome patients from healthy control subjects. Arthritis Rheum. 2005;52:1534–1544.
   PubMed Web of Science ®Google Scholar
• Nordmark G. Mechanisms of disease: primary Sjögren’s syndrome and the type I interferon system. Nat Clin Pract Rheumatol. 2006;2:262–269.
   PubMedGoogle Scholar
• Brkic Z, Maria NI, Van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren’s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013;72:728–735.
   PubMed Web of Science ®Google Scholar
• Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjogren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren’s related lymphomagenesis. J Autoimmun. 2015;63:47–58.
   PubMed Web of Science ®Google Scholar
• Woerkom JM, Van, Kruize AA, Wijk MJGW, et al. Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren’s sicca syndrome. Ann Rheum Dis. 2005;64:1474–1479.
   PubMed Web of Science ®Google Scholar
• Nakayamada S, Poholek A, Lu K, et al. Type I interferon induces binding of STAT1 to Bcl6: divergent roles of STAT-family transcription factors in the Tfh cell genetic program. J Immunol. 2014;192:2156–2166.
   PubMed Web of Science ®Google Scholar
• Domeier PP, Chodisetti SB, Soni C, et al. IFN- γ receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity. J Exp Med. 2016;213:715–732.
   PubMed Web of Science ®Google Scholar
• Velu V, Mylvaganam GH, Hong JJ, et al. Induction of Th1-biased T follicular helper (Tfh) cells in lymphoid tissues during chronic simian immunodeficiency virus infection defines functionally distinct germinal center Tfh cells. J Immunol. 2016;197:1832–1842.
   PubMed Web of Science ®Google Scholar
• Yu S, Jia L, Zhang Y, et al. IL-12 induced the generation of IL-21- and IFN- g -co-expressing poly-functional CD4+ T cells from human naive CD4+ T cells. Cell Cycle. 2015;14:3362–3372.
   PubMed Web of Science ®Google Scholar
• Risselada AP, Looije MF, Kruize AA, et al. The role of ectopic germinal centers in the immunopathology of primary Sjögren’s syndrome: a systematic review. Semin Arthritis Rheum. 2013;42:368–376.
   PubMed Web of Science ®Google Scholar
• Kruize A, Hene R, Kallenberg C, et al. Hydroxychloroquine treatment for primary Sjögren’s syndrome : a two year double blind cross over trial. Ann Rheum Dis. 1993;52:360–364.
   PubMed Web of Science ®Google Scholar
• Van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjögren’s syndrome: a phase II pilot study. Ann Rheum Dis. 2007;66:1026–1032.
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome the JOQUER randomized clinical trial. Jama. 2014;312:249–258.
   PubMed Web of Science ®Google Scholar
• Bruneau J-M, Yea CM, Spinella-Jaegle S, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J. 1998;336:299–303.
   PubMed Web of Science ®Google Scholar
• Siemasko K, Chong A, Williams J, et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation. 1996;61:635–642.
   PubMed Web of Science ®Google Scholar
• Abarientos C, Sperber K, Shapiro DL, et al. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Saf. 2011;10:705–714.
   PubMed Web of Science ®Google Scholar
• Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005;202:1171–1177.
   PubMed Web of Science ®Google Scholar
• Wallace D, Gudsoorkar V, Weisman S, et al. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8:522–533.
   PubMed Web of Science ®Google Scholar
• Kužnik A, Benčina M, Švajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186:4794–4804.
   PubMed Web of Science ®Google Scholar
• Pasquier B. Autophagy inhibitors. Cell Mol Life Sci. 2016;73:985–1001.
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–558.
   PubMed Web of Science ®Google Scholar
• Jager WD, Velthuis H, Prakken BJ, et al. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2003;10:133–139.
   PubMedGoogle Scholar
• van Roon E, Jansen T, van de Laar M, et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:569–574.
   PubMed Web of Science ®Google Scholar
• Mok CC. Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. Expert Rev Clin Immunol. 2016;13:1–7.
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Guern le V, Piette JC. Routine hydroxychloroquine blood concentration measurement in systemic lupus erythematosus reaches adulthood. J Rheumatol. 2015;42:1997–1999.
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160:233–242.
   PubMed Web of Science ®Google Scholar
• Meiners PM, Vissink A, Kroese GM, et al. Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014;73:1–4.
   PubMed Web of Science ®Google Scholar
• Adler S, Körner M, Förger F, et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary sjögren’s syndrome: A pilot study. Arthritis Care Res (Hoboken). 2013;65:1862–1868.
   PubMed Web of Science ®Google Scholar
• Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjögren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2013;74:1–6.
   Google Scholar
• van der Heijden EHM, Kruize AA, Radstake TRDJ, et al. Optimizing conventional DMARD therapy for Sjögren’s syndrome. Autoimmun Rev. 2018;17:480–492.
   PubMed Web of Science ®Google Scholar
• Carubbi. Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15:R172.
   PubMed Web of Science ®Google Scholar
• Alunno A, Carubbi F, Bistoni O, et al. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren’s syndrome: a pilot study. Clin Exp Rheumatol. 2016;184:284–292.
   Google Scholar
• Abdulahad WH, Meijer JM, Kroese FGM, et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren’s syndrome. Arthritis Rheum. 2011;63:1116–1123.
   PubMed Web of Science ®Google Scholar
• Verstappen GM, Kroese FGM, Meiners PM, et al. B cell depletion therapy normalizes circulating follicular th cells in primary Sjögren syndrome. J Rheumatol. 2017;44:49–58.
   PubMed Web of Science ®Google Scholar
• Hamza N, Bootsma H, Yuvaraj S, et al. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren’s syndrome after B cell depletion therapy. Ann Rheum Dis. 2012;71:1881–1887.
   PubMed Web of Science ®Google Scholar
• St Clair E, Levesque M, Prak E, et al. Rituximab therapy for primary Sjögren’s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65:1097–1106.
   PubMed Web of Science ®Google Scholar
• Radstake T, van der Heijden E, Moret F, et al. Clinical efficacy of leflunomide/hydroxychloroquine combination therapy in patients with primary Sjogren’s syndrome: results of a placebo-controlled double-blind randomized clinical trial [abstract]. Arthritis Rheumatol. 2018;70(suppl 10).
   Google Scholar